通过竞争性风险名谱进行射频剥离后T1/2肝细胞癌的癌症特异性死亡率的预测:基于人口的分析分析
Qifan He1, Yue Xiong1, Pengcheng Xia1
1Department of Radiology, Haining People's Hospital, Jiaxing, Zhejiang, China.
Clinics and research in hepatology and gastroenterology
|January 14, 2024
概括
本研究确定了在射频废除 (RFA) 后肝细胞癌 (HCC) 患者癌症特异性死亡率的关键风险因素. 开发了一种预后性脑图来预测结果,以帮助T1/2 HCC的临床管理.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 生物统计学 生物统计学
背景情况:
- 射频除 (RFA) 是早期肝细胞癌 (HCC) 的主要治疗方法.
- 确定癌症特异性死亡率 (CSM) 的风险因素对于RFA后的患者管理至关重要,但仍在争论中.
- 这项研究解决了用RFA治疗T1/2 HCC中精确预后工具的需求.
研究的目的:
- 为了确定与RFA治疗的T1/2 HCC患者中CSM的独立风险因素.
- 开发和验证用于预测CSM的预后名录.
- 加强临床决策和患者分层.
主要方法:
- 利用了来自SEER数据库的2,135名T1/2HCC患者的数据.
- 采用单变量和多变量竞争性风险分析来确定风险因素.
- 使用培训和验证套件构建和验证预后名录,评估ROC曲线,C指数,校准图和DCA的性能.
主要成果:
- 5年的CSM率为30.1%.
- CSM的独立风险因素包括瘤等级,大小,数量,肝硬化和AFP水平.
- 与AJCC阶段模型相比,开发的名图表显示出更高的预测准确性,C指数为0.65与0.55.
结论:
- 瘤等级,AFP水平,肝硬化,瘤大小和瘤数量是RFA后HCC患者中CSM显著的独立风险因素.
- 开发的竞争性风险名谱是一种高性能工具,用于预测接受RFA的HCC患者的CSM概率.
- 诺米图有助于将风险分为低风险,中风险和高风险群体进行分层,从而改善临床管理.
相关概念视频
01:21Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
01:20Actuarial Approach
79
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
79
01:24Kaplan-Meier Approach
146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146